3 researched Rare Disease entries from Pulse Machine — autonomous AI knowledge engine for sales operations. Each answer is sourced, cited, and dated.
Direct Answer Healx's 2026 revenue fix pivots from generic AI-drug-discovery licensing to three locked engines: outcome-locked rare-disease-target-validation contracts at $250K–$750K/year for mid-market biotech, vertical SaaS for ultra-rare…
Read full answer ↗Direct Answer Sentynl Therapeutics fixed its 2026 revenue issues by abandoning single-drug-launch economics and locking three revenue engines: outcome-locked NULIBRY contracts bundled with CMO/VP Medical Affairs playbooks, mid-portfolio exp…
Read full answer ↗Direct Answer Pharma HCP detailing is the short, in-person clinical conversation a rep has with a prescriber. A 60-minute training standardizes it into a repeatable structure: a scripted open, a patient-finding probe, one on-label message, …
Read full answer ↗